Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COUNTER-COVID imatinib trial in severe hospitalized COVID-19
NL-OMON49996Phase 2Completed
- Sponsor
- Vrije University Medical Center
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Imatinib with Placebo (2 arms). Primary endpoint: Time to liberation from ventilation and supplemental oxygen while alive. Started Mar 2020; status: completed.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON49996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49996.